Indegene Quarterly Results
Indegene quarterly results. In Sept 2026, Indegene (INDGN) reported revenue ₹1,137 Cr and net profit ₹112 Cr — revenue +38.0% YoY. Also explore Indegene share price performance to track price trends across different timeframes.
INDGN Quarterly Results — Revenue, Profit & EPS Highlights
Indegene latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. For annual financials, live price and key ratios, visit INDGN stock price BSE.
- Revenue of ₹1,137 Cr in Sept 2026 (+12.1% vs Mar 2026, +38.0% vs Sept 2025)
- Net Profit of ₹112 Cr in Sept 2026 (+40.0% vs Mar 2026, +9.8% vs Sept 2025)
- EBITDA of ₹201 Cr in Sept 2026 (+30.5% vs Mar 2026)
- Operating Margin of 17.0% in Sept 2026 (+3.0pp vs Mar 2026)
- Earnings Per Share of ₹4.67 in Sept 2026 (+40.7% vs Mar 2026)
Indegene Quarterly Results — Revenue, EBITDA, Net Profit & EPS
INDGN quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Sept 2026 | Mar 2026 | Jun 2026 | Sept 2025 | Mar 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 1,137 | 1,014 | 1,092 | 824 | 781 | 12.1% | 38.0% |
| Net Profit (₹ Cr) | 112 | 80 | 116 | 102 | 118 | - | - |
| EBITDA (₹ Cr) | 201 | 154 | 203 | 160 | 173 | - | - |
| EPS (₹) | 4.67 | 3.32 | 4.84 | 4.26 | 4.91 | - | - |
| Operating Margin (%) | 17.0% | 14.0% | 16.0% | 17.0% | 20.0% | - | - |
INDGN Share Price Trend — 1-Year Movement Across Quarterly Results
Indegene 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. View INDGN price range for the annual high/low range and current price position.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
INDGN vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Indegene latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Sept 2026 |
₹451,074.97 Cr | 1900.0 | 16,617 | 1,995 | +10.6% | - | 12.0% | 228.9 |
|
Divis Laboratories
Sept 2026 |
₹294,139.19 Cr | 11178.0 | 3,770 | 1,127 | +26.3% | - | 29.9% | 263.1 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹188,719.51 Cr | 4611.0 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 400.6 |
|
Apollo Hospitals
Sept 2026 |
₹126,832.45 Cr | 8738.0 | 7,673 | 660 | +15.2% | - | 8.6% | 199.4 |
|
Laurus Labs
Sept 2026 |
₹125,946.78 Cr | 2306.0 | 2,219 | 436 | +21.7% | - | 19.6% | 282.3 |
QoQ: Quarter over Quarter • YoY: Year over Year
All amounts in ₹ Crores